[Clinical trials for bladder cancer in Germany].
The urothelial cancer section of the Association of Urogenital Oncology (AUO) of the German Cancer Society has successfully performed and published clinical trials on treatment of urothelial neoplasia. During the last decade, around 770 patients have been recruited for several phase I, II and III trials. The majority of trials had been conceived for advanced inoperable stages, but the AUO has also been particularly successful in recruiting large trials on adjuvant chemotherapy after radical cystectomy for locally advanced bladder cancer. Future goals address extending the number of active centers in Germany as well as seeking international collaborations in order to enable timely recruitment of trials that demand an extensive sample size.
Lehmann
J
J
Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Homburg/Saar. jan.lehmann@uniklinikum-saarland.de
Böhle
A
A
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000639:trends; D002986:Clinical Trials as Topic / Q000639:trends*; D015195:Drug Design; D004341:Drug Evaluation / Q000639:trends*; D005858:Germany; D006801:Humans; D017430:Prostate-Specific Antigen / Q000097:blood; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000188:drug therapy*
D000970:Antineoplastic Agents; D017430:Prostate-Specific Antigen